{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:36:11Z","timestamp":1790516171143,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004083","name":"Ministry of Science ICT and Future Planning","doi-asserted-by":"publisher","award":["NRF-2017R1A5A2014768"],"award-info":[{"award-number":["NRF-2017R1A5A2014768"]}],"id":[{"id":"10.13039\/501100004083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostaglandins &amp; Other Lipid Mediators"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.prostaglandins.2017.12.002","type":"journal-article","created":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T21:47:43Z","timestamp":1514584063000},"page":"47-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Iloprost, a prostacyclin analog, inhibits the invasion of ovarian cancer cells by downregulating matrix metallopeptidase-2 (MMP-2) through the IP-dependent pathway"],"prefix":"10.1016","volume":"134","author":[{"given":"Ji-Hye","family":"Ahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Tae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youn Seok","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Hye","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prostaglandins.2017.12.002_bib0005","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.prostaglandins.2017.12.002_bib0010","first-page":"266","article-title":"Novel mechanisms and approaches to overcome multidrug resistance in the treatment of ovarian cancer","volume":"1866","author":"Ren","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"issue":"3\u20134","key":"10.1016\/j.prostaglandins.2017.12.002_bib0015","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF00666104","article-title":"Prostacyclin and its analogues: antimetastatic effects and mechanisms of action","volume":"13","author":"Schneider","year":"1994","journal-title":"Cancer Metastasis Rev."},{"issue":"6","key":"10.1016\/j.prostaglandins.2017.12.002_bib0020","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1742-1241.1990.tb10799.x","article-title":"The acute effect of the synthetic prostacyclin analogue iloprost in primary pulmonary hypertension","volume":"44","author":"Scott","year":"1990","journal-title":"Br. J. Clin. Pract."},{"issue":"3","key":"10.1016\/j.prostaglandins.2017.12.002_bib0025","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1164\/rccm.200502-296OC","article-title":"Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension","volume":"172","author":"Schermuly","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.prostaglandins.2017.12.002_bib0030","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1006\/jsre.1998.5312","article-title":"Prostaglandin I2 analogue, iloprost, down regulates mitogen-activated protein kinases of macrophages","volume":"76","author":"Lo","year":"1998","journal-title":"J. Surg. Res."},{"issue":"3","key":"10.1016\/j.prostaglandins.2017.12.002_bib0035","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1593\/neo.91690","article-title":"Prostacyclin inhibits non-small cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1","volume":"12","author":"Tennis","year":"2010","journal-title":"Neoplasia"},{"issue":"6","key":"10.1016\/j.prostaglandins.2017.12.002_bib0040","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0090-6980(90)90020-V","article-title":"Effects of a stable prostacyclin analogue on platelet activity and on host immunocompetence in mice","volume":"39","author":"Costantini","year":"1990","journal-title":"Prostaglandins"},{"issue":"6","key":"10.1016\/j.prostaglandins.2017.12.002_bib0045","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/BF01753677","article-title":"Antimetastatic action of the prostacyclin analog iloprost in the mouse","volume":"7","author":"Sava","year":"1989","journal-title":"Clin. Exp. Metastasis"},{"issue":"5","key":"10.1016\/j.prostaglandins.2017.12.002_bib0050","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00296-011-1848-4","article-title":"Possible anti-metastatic effect of iloprost in a patient with systemic sclerosis with lung cancer: a case study","volume":"32","author":"Pehlivan","year":"2012","journal-title":"Rheumatol. Int."},{"issue":"2","key":"10.1016\/j.prostaglandins.2017.12.002_bib0055","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.trsl.2009.06.010","article-title":"The role of prostacyclin in lung cancer","volume":"155","author":"Tennis","year":"2010","journal-title":"Transl. Res."},{"issue":"11","key":"10.1016\/j.prostaglandins.2017.12.002_bib0060","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.1158\/0008-5472.CAN-07-0828","article-title":"Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer","volume":"67","author":"Daikoku","year":"2007","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.prostaglandins.2017.12.002_bib0065","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/sj.bjp.0701367","article-title":"Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells","volume":"122","author":"Kiriyama","year":"1997","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.prostaglandins.2017.12.002_bib0070","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrc745","article-title":"New functions for the matrix metalloproteinases in cancer progression","volume":"2","author":"Egeblad","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"17","key":"10.1016\/j.prostaglandins.2017.12.002_bib0075","first-page":"5224","article-title":"Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation","volume":"63","author":"Belotti","year":"2003","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.prostaglandins.2017.12.002_bib0080","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1172\/JCI33775","article-title":"The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin","volume":"118","author":"Kenny","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.prostaglandins.2017.12.002_bib0085","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1309\/B1YX-L8DB-TGY1-7905","article-title":"Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions","volume":"115","author":"Davidson","year":"2001","journal-title":"Am. J. Clin. Pathol."},{"issue":"15","key":"10.1016\/j.prostaglandins.2017.12.002_bib0090","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/jnci\/94.15.1134","article-title":"Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice","volume":"94","author":"Huang","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.prostaglandins.2017.12.002_bib0095","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s10517-010-1010-4","article-title":"Matrix metalloproteinases 2, 7, and 9 and tissue inhibitor of metalloproteinases-1 in tumors and serum of patients with ovarian neoplasms","volume":"149","author":"Gershtein","year":"2010","journal-title":"Bull. Exp. Biol. Med."},{"issue":"13","key":"10.1016\/j.prostaglandins.2017.12.002_bib0100","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0959-8049(03)00427-1","article-title":"Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma","volume":"39","author":"Manenti","year":"2003","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.prostaglandins.2017.12.002_bib0105","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/01616412.1993.11740172","article-title":"Effects of prostacyclin analogue iloprost on the regional cerebral blood flow in transplanted rat brain tumour","volume":"15","author":"Nomura","year":"1993","journal-title":"Neurol. Res."},{"issue":"6","key":"10.1016\/j.prostaglandins.2017.12.002_bib0110","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1349-7006.2012.02261.x","article-title":"Prostacyclin receptor in tumor endothelial cells promotes angiogenesis in an autocrine manner","volume":"103","author":"Osawa","year":"2012","journal-title":"Cancer Sci."},{"issue":"3","key":"10.1016\/j.prostaglandins.2017.12.002_bib0115","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.2353\/ajpath.2010.100316","article-title":"Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin","volume":"177","author":"Park","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"5","key":"10.1016\/j.prostaglandins.2017.12.002_bib0120","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1182\/blood-2013-07-512384","article-title":"Time-resolved characterization of cAMP\/PKA-dependent signaling reveals that platelet inhibition is a concerted process involving multiple signaling pathways","volume":"123","author":"Beck","year":"2014","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.prostaglandins.2017.12.002_bib0125","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1096\/fj.02-0204fje","article-title":"Prostacyclin derivatives prevent the fibrotic response to TGF-beta by inhibiting the Ras\/MEK\/ERK pathway","volume":"16","author":"Stratton","year":"2002","journal-title":"FASEB J."},{"issue":"5","key":"10.1016\/j.prostaglandins.2017.12.002_bib0130","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.yjmcc.2009.01.006","article-title":"Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation","volume":"46","author":"Kasza","year":"2009","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"3","key":"10.1016\/j.prostaglandins.2017.12.002_bib0135","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1158\/1541-7786.MCR-06-0221","article-title":"Genetic and epigenetic regulation of the human prostacyclin synthase promoter in lung cancer cell lines","volume":"5","author":"Stearman","year":"2007","journal-title":"Mol. Cancer Res."},{"issue":"5 Suppl","key":"10.1016\/j.prostaglandins.2017.12.002_bib0140","doi-asserted-by":"crossref","first-page":"141S","DOI":"10.1378\/chest.125.5_suppl.141S","article-title":"Prostacyclin in human non-small cell lung cancers","volume":"125","author":"Nana-Sinkam","year":"2004","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.prostaglandins.2017.12.002_bib0145","first-page":"988","article-title":"Prostaglandin and thromboxane synthesis by M5076 ovarian reticulosarcoma during growth: effects of a thromboxane synthetase inhibitor","volume":"47","author":"Chiabrando","year":"1987","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.prostaglandins.2017.12.002_bib0150","first-page":"1604","article-title":"Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors","volume":"9","author":"Ermert","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.prostaglandins.2017.12.002_bib0155","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3181\/00379727-172-41548","article-title":"PGE2 and angiogenesis","volume":"172","author":"Form","year":"1983","journal-title":"Soc. Exp. Biol. Med."},{"issue":"1","key":"10.1016\/j.prostaglandins.2017.12.002_bib0160","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1006\/bbrc.1999.1840","article-title":"Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis, Biochem","volume":"267","author":"Nie","year":"2000","journal-title":"Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.prostaglandins.2017.12.002_bib0165","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2183\/pjab.93.044","article-title":"Prostaglandin terminal synthases as novel therapeutic targets","volume":"93","author":"Hara","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"issue":"3","key":"10.1016\/j.prostaglandins.2017.12.002_bib0170","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/187152006776930882","article-title":"The potential and rationale for COX-2 inhibitors in lung cancer","volume":"6","author":"Krysan","year":"2006","journal-title":"Anticancer Agents Med. Chem."},{"issue":"1072","key":"10.1016\/j.prostaglandins.2017.12.002_bib0175","first-page":"305","article-title":"Prostacyclin: its biosynthesis, actions and clinical potential, Philos","volume":"294","author":"Moncada","year":"1981","journal-title":"Trans. R. Soc. Lond. B Biol. Sci."},{"issue":"1","key":"10.1016\/j.prostaglandins.2017.12.002_bib0180","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/gut.2004.047100","article-title":"Prostaglandins and cancer","volume":"55","author":"Wang","year":"2006","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.prostaglandins.2017.12.002_bib0185","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1158\/1940-6207.CAPR-08-0145","article-title":"Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator\u2013activated receptor gamma","volume":"1","author":"Nemenoff","year":"2008","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.prostaglandins.2017.12.002_bib0190","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.prostaglandins.2017.05.001","article-title":"Role of prostacyclin synthase in carcinogenesis","volume":"133","author":"Sasaki","year":"2017","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.prostaglandins.2017.12.002_bib0195","doi-asserted-by":"crossref","first-page":"17376","DOI":"10.1038\/srep17376","article-title":"Genetic-deletion of cyclooxygenase-2 downstream prostacyclin synthase suppresses inflammatory reactions but facilitates carcinogenesis, unlike deletion of microsomal prostaglandin e synthase-1","volume":"5","author":"Sasaki","year":"2015","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.prostaglandins.2017.12.002_bib0200","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/ERC-13-0450","article-title":"COX2 and PGE2 mediate EGF-induced E-cadherin-independent human ovarian cancer cell invasion","volume":"21","author":"Qiu","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"issue":"7","key":"10.1016\/j.prostaglandins.2017.12.002_bib0205","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1210\/en.2009-1318","article-title":"Gonadotropins induce tumor cell migration and invasion by increasing cyclooxygenases expression and prostaglandin E(2) production in human ovarian cancer cells","volume":"151","author":"Lau","year":"2010","journal-title":"Endocrinology"},{"issue":"18","key":"10.1016\/j.prostaglandins.2017.12.002_bib0210","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/onc.2015.302","article-title":"Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis","volume":"35","author":"Nagaraja","year":"2016","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.prostaglandins.2017.12.002_bib0215","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.joca.2006.10.003","article-title":"BCP crystals increase prostacyclin production and upregulate the prostacyclin receptor in OA synovial fibroblasts: potential effects on mPGES1 and MMP-13","volume":"15","author":"Molloy","year":"2007","journal-title":"Osteoarthritis Cartilage"},{"issue":"5\u20136","key":"10.1016\/j.prostaglandins.2017.12.002_bib0220","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1054\/plef.2001.0322","article-title":"Pharmacology of functional endogenous IP prostanoid receptors in NCB-20 cells: comparison with binding data from human platelets","volume":"65","author":"Crider","year":"2001","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"issue":"8","key":"10.1016\/j.prostaglandins.2017.12.002_bib0225","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1080\/02841860701403061","article-title":"Prostanoid receptor expression in colorectal cancer related to tumor stage, differentiation and progression","volume":"46","author":"Gustafsson","year":"2007","journal-title":"Acta Oncol."},{"key":"10.1016\/j.prostaglandins.2017.12.002_bib0230","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1755-8794-2-71","article-title":"Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells","volume":"2","author":"Bowen","year":"2009","journal-title":"BMC Med. Genomics"},{"issue":"9","key":"10.1016\/j.prostaglandins.2017.12.002_bib0235","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1073\/pnas.94.9.4312","article-title":"Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta","volume":"94","author":"Forman","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.prostaglandins.2017.12.002_bib0240","first-page":"3966","article-title":"Prostacyclin primes pregnant human myometrium for an enhanced contractile response in parturition","volume":"118","author":"Fetalvero","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.prostaglandins.2017.12.002_bib0245","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1165\/rcmb.2007-0009OC","article-title":"Prostacyclin analogs inhibit fibroblast contraction of collagen gels through the cAMP-PKA pathway","volume":"37","author":"Kamio","year":"2007","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"5","key":"10.1016\/j.prostaglandins.2017.12.002_bib0250","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.plefa.2013.08.006","article-title":"Prostaglandin I2-IP signalling regulates human th17 and treg cell differentiation","volume":"89","author":"Liu","year":"2013","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"issue":"3","key":"10.1016\/j.prostaglandins.2017.12.002_bib0255","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1161\/ATVBAHA.107.159483","article-title":"Transcriptional inhibition of protease-activated receptor-1 expression by prostacyclin in human vascular smooth muscle cells","volume":"28","author":"Pape","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"17","key":"10.1016\/j.prostaglandins.2017.12.002_bib0260","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1089\/ars.2013.5374","article-title":"Prostacyclin signaling boosts NADPH oxidase 4 in the endothelium promoting cytoprotection and angiogenesis","volume":"20","author":"Peshavariya","year":"2014","journal-title":"Antioxid. Redox Signal."},{"issue":"5","key":"10.1016\/j.prostaglandins.2017.12.002_bib0265","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00395-012-0287-z","article-title":"The prostacyclin agonist iloprost aggravates fibrosis and enhances viral replication in enteroviral myocarditis by modulation of ERK signaling and increase of iNOS expression","volume":"107","author":"Gruhle","year":"2012","journal-title":"Basic Res. Cardiol."},{"issue":"11","key":"10.1016\/j.prostaglandins.2017.12.002_bib0270","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.cellsig.2005.02.003","article-title":"The cAMP signalling pathway activates CREB through PKA, p38 and MSK1 in NIH 3T3 cells","volume":"17","author":"Delghandi","year":"2005","journal-title":"Cell. Signal."}],"container-title":["Prostaglandins &amp; Other Lipid Mediators"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882317300552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882317300552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:59:44Z","timestamp":1761098384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098882317300552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":54,"alternative-id":["S1098882317300552"],"URL":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2017.12.002","relation":{},"ISSN":["1098-8823"],"issn-type":[{"value":"1098-8823","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Iloprost, a prostacyclin analog, inhibits the invasion of ovarian cancer cells by downregulating matrix metallopeptidase-2 (MMP-2) through the IP-dependent pathway","name":"articletitle","label":"Article Title"},{"value":"Prostaglandins & Other Lipid Mediators","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2017.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}